265 related articles for article (PubMed ID: 28267648)
1. Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy.
Kristensen AM; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Höllsberg P; Deleuran B; Hvid M
Cytokine; 2017 Aug; 96():1-7. PubMed ID: 28267648
[TBL] [Abstract][Full Text] [Related]
2. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients.
Hock BD; O'Donnell JL; Taylor K; Steinkasserer A; McKenzie JL; Rothwell AG; Summers KL
Tissue Antigens; 2006 Jan; 67(1):57-60. PubMed ID: 16451202
[TBL] [Abstract][Full Text] [Related]
3. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
[TBL] [Abstract][Full Text] [Related]
4. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
5. Eukaryotic expression of functionally active recombinant soluble CD83 from HEK 293T cells.
Staab C; Mühl-Zürbes P; Steinkasserer A; Kummer M
Immunobiology; 2010; 215(9-10):849-54. PubMed ID: 20576314
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity.
Heftdal LD; Stengaard-Pedersen K; Ørnbjerg LM; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B; Møller HJ; Greisen SR
Scand J Clin Lab Invest; 2017 Sep; 77(5):385-389. PubMed ID: 28598681
[TBL] [Abstract][Full Text] [Related]
7. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
8. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera.
Hock BD; Kato M; McKenzie JL; Hart DN
Int Immunol; 2001 Jul; 13(7):959-67. PubMed ID: 11431426
[TBL] [Abstract][Full Text] [Related]
9. Putative loss of CD83 immunosuppressive activity in long-standing complication-free juvenile diabetic patients during disease progression.
Juhas U; Ryba-Stanisławowska M; Ławrynowicz U; Myśliwiec M; Myśliwska J
Immunol Res; 2019 Feb; 67(1):70-76. PubMed ID: 30937729
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner.
Royzman D; Andreev D; Stich L; Rauh M; Bäuerle T; Ellmann S; Boon L; Kindermann M; Peckert K; Bozec A; Schett G; Steinkasserer A; Zinser E
Front Immunol; 2019; 10():633. PubMed ID: 31001257
[TBL] [Abstract][Full Text] [Related]
11. Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis.
Neidhart M; Wehrli R; Brühlmann P; Michel BA; Gay RE; Gay S
Arthritis Rheum; 1999 Apr; 42(4):622-30. PubMed ID: 10211875
[TBL] [Abstract][Full Text] [Related]
12. Crystal Structure of the Extracellular Domain of the Human Dendritic Cell Surface Marker CD83.
Heilingloh CS; Klingl S; Egerer-Sieber C; Schmid B; Weiler S; Mühl-Zürbes P; Hofmann J; Stump JD; Sticht H; Kummer M; Steinkasserer A; Muller YA
J Mol Biol; 2017 Apr; 429(8):1227-1243. PubMed ID: 28315353
[TBL] [Abstract][Full Text] [Related]
13. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
Mathsson L; Lampa J; Mullazehi M; Rönnelid J
Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
[TBL] [Abstract][Full Text] [Related]
14. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
[TBL] [Abstract][Full Text] [Related]
15. Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response.
Kragstrup TW; Jalilian B; Keller KK; Zhang X; Laustsen JK; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hauge EM; Hvid M; Vorup-Jensen T; Deleuran B
PLoS One; 2016; 11(2):e0148486. PubMed ID: 26849368
[TBL] [Abstract][Full Text] [Related]
16. The expression and characterization of functionally active soluble CD83 by Pichia pastoris using high-density fermentation.
Guo Y; Li R; Song X; Zhong Y; Wang C; Jia H; Wu L; Wang D; Fang F; Ma J; Kang W; Sun J; Tian Z; Xiao W
PLoS One; 2014; 9(2):e89264. PubMed ID: 24586642
[TBL] [Abstract][Full Text] [Related]
17. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
18. The levels of soluble forms of CD21 and CD83 in multiple sclerosis.
Karampoor S; Zahednasab H; Etemadifar M; Keyvani H
J Neuroimmunol; 2018 Jul; 320():11-14. PubMed ID: 29759135
[TBL] [Abstract][Full Text] [Related]
19. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
Kubota A; Hasegawa K; Suguro T; Koshihara Y
J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
